Liver transplantation for intrahepatic cholangiocarcinoma: a narrative review of the latest advances

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a rare tumor that arises from second order or smaller bile ducts. Its incidence has been growing in the last couple of decades, in parallel with its mortality rates, both in America and Europe. The currently accepted gold treatment for iCCA is liver resection (LR). However, results are still poor, with 5-year survival rates ranging between 25% and 40%. In addition, more than half of the patients undergoing LR will relapse, particularly those who present with multifocal iCCA. Given the aggressiveness of this tumor, and the modest results seen with adjuvant and neoadjuvant therapies, the sights have been set on liver transplantation (LT) for this disease. Retrospective studies have shown encouraging results in select patients, especially those with very early-staged iCCA (< 2 cm) who underwent LT. The aim of this review is to analyze the current information regarding LT for iCCA, as well as future perspectives.

Keywords

Intrahepatic cholangiocarcinoma / LT / iCCA

References

[1] Gupta A.Epidemiology and risk factors: intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr2017;6:101-4 PMCID:PMC5411279

[2] Kendall T,Gaudio E.Anatomical, histomorphological and molecular classification of cholangiocarcinoma.Liver Int2019;39 Suppl 1:7-18

[3] Liao X.The 8th edition american joint committee on cancer staging for hepato-pancreato-biliary cancer: a review and update.Arch Pathol Lab Med2021;145:543-153

[4] Nakanuma Y.Pathologic classification of cholangiocarcinoma: new concepts.Best Pract Res Clin Gastroenterol2015;29:277-93

[5] Dodson RM,Cosgrove D.Intrahepatic cholangiocarcinoma: management options and emerging therapies.J Am Coll Surg2013;217:736-750.e4.

[6] Poultsides GA,Choti MA.Intrahepatic cholangiocarcinoma.Surg Clin North Am2010;90:817-37

[7] Van Dyke AL,Jones GS.Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.Cancer2019;125:1489-98 PMCID:PMC6467796

[8] Wu L,Paredes AZ.Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival.World J Surg2019;43:1777-87

[9] Xing H,Yang C.Incidence trend and competing risk analysis of patients with intrahepatic cholangiocarcinoma: a population-based study.Front Med2022;9:846276 PMCID:PMC9005886

[10] Khan SA,Morement H,Rous B.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:1261-2

[11] Bertuccio P,Carioli G.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:104-14.

[12] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.J Hepatol2020;72:95-103

[13] Petrick JL,Altekruse SF.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare.PLoS One2017;12:e0186643 PMCID:PMC5648218

[14] Zhou Y,Li B.Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis.BMC Can-cer2012;12:289 PMCID:PMC3411483

[15] Li M,Li P.Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review.J Gastroenterol Hepatol2012;27:1561-8.

[16] Chinchilla-López P,García-Gómez J.Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma.Ann Hepatol2017;16:565-8

[17] Barner-Rasmussen N,Hadkhale K.Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.United European Gastroenterol J2021;9:1128-35. PMCID:PMC8672081

[18] Izquierdo-Sanchez L,La Casta A.Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA registry.J Hepatol2022;76:1109-21

[19] Amini N,Spolverato G,Herman JM.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis.J Surg Oncol2014;110:163-70

[20] Spolverato G,Cucchetti A.Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?.Cancer2015;121:3998-4006.

[21] Edeline J,Bertaut A.Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.Eur J Cancer2022;164:80-7.

[22] Choi SH,Kim SY.Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT.Radiology2017;282:771-81.

[23] Park S,Kim H.Subtype classification of intrahepatic cholangiocarcinoma using liver MR imaging features and its prognostic value.Liver Cancer2022;11:233-46 PMCID:PMC9218635

[24] Rhee H,Park YN.A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.Eur Radiol2019;29:3111-21

[25] Seo N,Choi JY.Cross-Sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis.AJR Am J Roentgenol2017;209:W64-75

[26] Sheng R,Zhang Y.MRI for hepatitis B-Associated intrahepatic cholangiocarcinoma: A multicenter comparative study.J Magn Reson Imaging2023;Online ahead of print

[27] Liang B,He Q.Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis.Med Sci Monit2015;21:3555-63 PMCID:PMC4655615

[28] Wei F,Zhao YQ,Chen F.Expression of m6A RNA methylation regulators and their clinical predictive value in intrahepatic cholangiocarcinoma.Front Biosci2023;28:120

[29] Liang Z,Zhang Q,Zhao Y.Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma.Dig Liver Dis2016;48:1227-32.

[30] Tanaka H,Baba Y.Usefulness of endoscopic transpapillary tissue sampling for malignant biliary strictures and predictive factors of diagnostic accuracy.Clin Endosc2018;51:174-80 PMCID:PMC5903074

[31] Nanda A,Berger SH.Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma.Therap Adv Gastroenterol2015;8:56-65 PMCID:PMC4314305

[32] Kobayashi M,Araki R.Investigation of factors affecting the sensitivity of bile duct brush cytology.Intern Med2019;58:329-35 PMCID:PMC6395130

[33] Kim DH,Choi SH,Kow AW.Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma?.Surgery2015;157:666-75.

[34] Nakagohri T,Konishi M,Gotohda N.Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma.World J Surg2008;32:2675-80

[35] Lang H,Heinrich S.Liver resection for intrahepatic cholangiocarcinoma-single-center experience with 286 patients undergoing surgical exploration over a thirteen year period.J Clin Med2021;10:3559 PMCID:PMC8396970

[36] Sotiropoulos GC,Sgourakis G.R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis.Dig Dis Sci2009;54:887-94

[37] Si A,Yang Z.Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma.Ann Surg Oncol2019;26:1841-50

[38] Paik KY,Heo JS,Choi DW.What prognostic factors are important for resected intrahepatic cholangiocarcinoma?.J Gastroenterol Hepatol2008;23:766-70

[39] Becker NS,Barshes NR,Goss JA.Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.J Gastrointest Surg2008;12:117-22.

[40] Goldstein RM,Tillery GW.Is liver transplantation indicated for cholangiocarcinoma?.Am J Surg1993;166:768-71; discussion 771

[41] O'Grady JG,Rolles K,Williams R.Liver transplantation for malignant disease. Results in 93 consecutive patients.Ann Surg1988;207:373-9. PMCID:PMC1493443

[42] Yokoyama I,Iwatsuki S.Liver transplantation in the treatment of primary liver cancer.Hepatogastroenterology1990;37:188-93 PMCID:PMC2967752

[43] Meyer CG,James L.Liver transplantation for cholangiocarcinoma: results in 207 patients.Transplantation2000;69:1633-7

[44] Shimoda M,Colquhoun SD.Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.Liver Transpl2001;7:1023-33

[45] Robles R,Turrión VS.Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma.Ann Surg2004;239:265-71. PMCID:PMC1356221

[46] Ghali P,Yoshida EM.Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience.Liver Transpl2005;11:1412-6.

[47] Vilchez V,Daily MF.Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.HPB2016;18:29-34 PMCID:PMC4750226

[48] Sapisochin G,Gastaca M."Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?.Am J Transplant2014;14:660-7

[49] Sapisochin G,Rubbia-Brandt L.iCCA International ConsortiumLiver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.Hepatology2016;64:1178-88

[50] Pichlmayr R.Is there a place for liver grafting for malignancy?.Transplant Proc1988;20:478-82

[51] Sotiropoulos GC,Lang H.Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience.Transplant Proc2008;40:3194-5

[52] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J Hepatol2022;76:681-93. PMCID:PMC8866082

[53] Gores GJ,Heimbach JK.Liver transplantation for perihilar cholangiocarcinoma.Dig Dis2013;31:126-9

[54] Clavien PA,Bossuyt PM,Langer B.OLT for HCC Consensus GroupRecommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.Lancet Oncol2012;13:e11-22. PMCID:PMC3417764

[55] Sapisochin G,Lerut J.Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference.Transplantation2020;104:1125-30.

[56] Liver Transplantation for Early Intrahepatic Cholangiocarcinoma (LT for iCCA). Available from: https://clinicaltrials.gov/ct2/show/NCT02878473 [Last accessed on 27 Jul 2023]

[57] Ziogas IA,Economopoulos KP.Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates.Transplantation2021;105:2263-71

[58] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9.

[59] Yao FY,Bass NM.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001;33:1394-403

[60] Takahashi K,Burmeister CS.Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis.Ann Transplant2016;21:208-15

[61] De Martin E,Golse N.Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis.Liver Transpl2020;26:785-98

[62] Rayar M,Edeline J.Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.Ann Surg Oncol2015;22:3102-8

[63] Rayar M,Houssel-Debry P,Sulpice L.Multimodal therapy including Yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma.J Gastrointestin Liver Dis2016;25:401-4

[64] Hong JC,Duffy JP.Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.Arch Surg2011;146:683-9

[65] Ito T,Noguchi D.A 3-Decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy.Liver Transpl2022;28:386-96.

[66] Lunsford KE,Heyne K.Methodist0-MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC)Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.Lancet Gastroenterol Hepatol2018;3:337-48.

[67] McMillan RR,Kodali S.Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma.Am J Transplant2022;22:823-32

[68] Nakachi K,Konishi M.Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet2023;401:195-203.

[69] Hu LS,Weiss M.Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma.Ann Surg Oncol2019;26:2549-57

[70] Tsilimigras DI,Wu L.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches.JAMA Surg2020;155:823-31 PMCID:PMC7344787

[71] Doussot A,Wiggers JK.Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models.J Am Coll Surg2016;223:493-505.e2 PMCID:PMC5003652

[72] Khan SA,Brandi G.Cholangiocarcinoma: epidemiology and risk factors.Liver Int2019;39 Suppl 1:19-31

[73] Tyson GL.Risk factors for cholangiocarcinoma.Hepatology2011;54:173-84 PMCID:PMC3125451

[74] Hyder O,Pulitano C.A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.JAMA Surg2014;149:432-8

[75] Sahara K,Mehta R.A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the "metro-ticket" paradigm.J Surg Oncol2019;120:223-30

[76] Choi WJ,Gravely A.Preoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection.Ann Hepatobiliary Pancreat Surg2023;27:158-65 PMCID:PMC10201063

[77] Bo Z,Yang Y.Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: a multicentre cohort study.Eur J Nucl Med Mol Imaging2023;50:2501-13

[78] Alaimo L,Moazzam Z.ASO visual abstract: development and validation of a machine learning model to predict early recurrence of intrahepatic cholangiocarcinoma.Ann Surg Oncol2023;Online ahead of print

[79] Chu H,Liang W.Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma.Eur Radiol2021;31:2368-76.

[80] Vallin M,Lamblin G.Unrecognized intrahepatic cholangiocarcinoma: an analysis of 993 adult cirrhotic liver explants.Clin Transplant2013;27:403-9.

[81] Lindnér P,Hafström L.The impact of changed strategies for patients with cholangiocarcinoma in this millenium.HPB Surg2015;2015:736049 PMCID:PMC4348584

[82] Facciuto ME,Lubezky N.Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation.Transplantation2015;99:151-7

[83] Jung DH,Song GW.Clinicopathological features and prognosis of intrahepatic cholangiocarcinoma after liver transplantation and resection.Ann Transplant2017;22:42-52

[84] Lee DD,Musto KR.Liver transplantation for intrahepatic cholangiocarcinoma.Liver Transpl2018;24:634-44

[85] Krasnodębski M,Jastrzębski M.Unsatisfactory long-term results of liver transplant in patients with intrahepatic cholangiocarcinoma.Transplant Proc2020;52:2463-7